article thumbnail

Three Big Questions for Stage 3 & Patient Engagement

Chilmark Research

For many, the delay of Stage 3 of the Meaningful Use program evoked a collective sigh of relief, providing a much-needed extra year to focus on the challenging requirements for patient engagement and interoperability. care partners or those who assist them) to help address a health concern.”. How Will the Market Respond?

article thumbnail

Review of Mobile Devices and Health by Ida Sim in the NEJM

mHealth Insight

Simultaneously, these biomarkers must be of sufficient direct value to patients to justify their participation in the data-collection effort. Greater investment in the science of digital biomarkers is needed to evaluate the value of mobile health data for clinical use. “Digital Therapeutics and Diagnostics.